Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role, a press release reports, Jaff will lead clinical and medical affairs strategies to support the development and commercialisation of the company’s peripheral vascular medical device portfolio, and drive engagement with external stakeholders to advance technologies that deliver strong clinical value and enable patient care.
The press release adds that Jaff is currently president of Newton-Wellesley Hospital (part of the Partners Healthcare system in Massachusetts), “where he has been instrumental in the hospital’s growth since 2016”. Previously, he was responsible for process improvement efforts to redesign healthcare delivery at Massachusetts General Hospital and led its Fireman Vascular Center.
With more than 25 years of experience as a vascular clinician, his research has been published in more than 300 peer reviewed medical journals. Jaff is also the founder of VasCore, which is the world’s largest core laboratory for non-invasive vascular imaging and clinical trials. Furthermore, he is currently professor of medicine at Harvard Medical School and has served on multiple professional society and hospital boards of directors.
Jaff says: “I have had the privilege of collaborating with Boston Scientific over the course of my career and have participated in numerous clinical trials investigating the company’s devices. The Boston Scientific culture of innovation, dedication to the highest ethical approach to interventional therapies and commitment to bringing forward solutions that improve the care of patients made this the best decision for the next phase of my career.”
Jeff Mirviss, senior vice president and president, peripheral interventions, Boston Scientific, comments: “Michael’s experience as a clinician, researcher and hospital administrator will bring a unique perspective in our efforts to help solve complex healthcare challenges and support our customers in advancing the care of patients suffering from debilitating vascular diseases and conditions. We are looking forward to Michael joining our Boston Scientific team.”